• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COPD 患者 1 秒用力呼气容积随时间的变化。

Changes in forced expiratory volume in 1 second over time in COPD.

机构信息

Respiratory Section, Hvidovre Hospital, Hvidovre, Denmark.

出版信息

N Engl J Med. 2011 Sep 29;365(13):1184-92. doi: 10.1056/NEJMoa1105482. Epub 2011 Sep 26.

DOI:10.1056/NEJMoa1105482
PMID:21991892
Abstract

BACKGROUND

A key feature of chronic obstructive pulmonary disease (COPD) is an accelerated rate of decline in forced expiratory volume in 1 second (FEV(1)), but data on the variability and determinants of this change in patients who have established disease are scarce.

METHODS

We analyzed the changes in FEV(1) after administration of a bronchodilator over a 3-year period in 2163 patients. A random-coefficient model was used to evaluate possible predictors of both FEV(1) levels and their changes over time.

RESULTS

The mean (±SE) rate of change in FEV(1) was a decline of 33±2 ml per year, with significant variation among the patients studied. The between-patient standard deviation for the rate of decline was 59 ml per year. Over the 3-year study period, 38% of patients had an estimated decline in FEV(1) of more than 40 ml per year, 31% had a decline of 21 to 40 ml per year, 23% had a change in FEV(1) that ranged from a decrease of 20 ml per year to an increase of 20 ml per year, and 8% had an increase of more than 20 ml per year. The mean rate of decline in FEV(1) was 21±4 ml per year greater in current smokers than in current nonsmokers, 13±4 ml per year greater in patients with emphysema than in those without emphysema, and 17±4 ml per year greater in patients with bronchodilator reversibility than in those without reversibility.

CONCLUSIONS

The rate of change in FEV(1) among patients with COPD is highly variable, with increased rates of decline among current smokers, patients with bronchodilator reversibility, and patients with emphysema.

摘要

背景

慢性阻塞性肺疾病(COPD)的一个主要特征是 1 秒用力呼气量(FEV1)的下降速度加快,但关于已确诊疾病患者中这种变化的可变性和决定因素的数据很少。

方法

我们分析了 2163 例患者在 3 年内使用支气管扩张剂后 FEV1 的变化。使用随机系数模型来评估 FEV1 水平及其随时间变化的可能预测因素。

结果

FEV1 的平均(±SE)变化率为每年下降 33±2ml,患者之间存在显著差异。患者之间每年下降率的标准差为 59ml。在 3 年的研究期间,38%的患者预计 FEV1 每年下降超过 40ml,31%的患者每年下降 21-40ml,23%的患者 FEV1 变化范围为每年下降 20ml 至增加 20ml,8%的患者每年增加超过 20ml。与当前不吸烟者相比,当前吸烟者的 FEV1 年平均下降率高 21±4ml,肺气肿患者比无肺气肿患者高 13±4ml,支气管扩张剂可逆性患者比无可逆性患者高 17±4ml。

结论

COPD 患者的 FEV1 变化率差异很大,吸烟者、支气管扩张剂可逆性患者和肺气肿患者的下降率更高。

相似文献

1
Changes in forced expiratory volume in 1 second over time in COPD.COPD 患者 1 秒用力呼气容积随时间的变化。
N Engl J Med. 2011 Sep 29;365(13):1184-92. doi: 10.1056/NEJMoa1105482. Epub 2011 Sep 26.
2
Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease.支气管扩张剂反应性作为已确诊慢性阻塞性肺疾病的一种表型特征。
Thorax. 2012 Aug;67(8):701-8. doi: 10.1136/thoraxjnl-2011-201458. Epub 2012 Jun 13.
3
[Comparison of lung volume response with airflow response to bronchodilator in patients with chronic obstructive pulmonary disease].[慢性阻塞性肺疾病患者肺容积反应与支气管扩张剂气流反应的比较]
Zhonghua Jie He He Hu Xi Za Zhi. 2010 Feb;33(2):109-13.
4
Risk Factors of FEV₁/FVC Decline in COPD Patients.慢性阻塞性肺疾病患者第一秒用力呼气容积/用力肺活量下降的危险因素。
J Korean Med Sci. 2025 Feb 17;40(6):e32. doi: 10.3346/jkms.2025.40.e32.
5
Comparison of the variability of the annual rates of change in FEV₁ determined from serial measurements of the pre- versus post-bronchodilator FEV₁ over 5 years in mild to moderate COPD: results of the lung health study.比较轻度至中度 COPD 患者支气管扩张剂前后的 5 年系列测定的 FEV₁ 年变化率的变异性:肺健康研究结果。
Respir Res. 2012 Aug 15;13(1):70. doi: 10.1186/1465-9921-13-70.
6
Evaluation of COPD progression based on spirometry and exercise capacity.基于肺活量测定和运动能力评估慢性阻塞性肺疾病的进展。
Pneumonol Alergol Pol. 2013;81(4):288-93.
7
Biomarkers of collagen turnover are related to annual change in FEV in patients with chronic obstructive pulmonary disease within the ECLIPSE study.在 ECLIPSE 研究中,慢性阻塞性肺疾病患者的胶原代谢生物标志物与 FEV 的年度变化相关。
BMC Pulm Med. 2017 Dec 4;17(1):164. doi: 10.1186/s12890-017-0505-4.
8
Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.噻托溴铵对中度慢性阻塞性肺疾病患者预后的影响(UPLIFT):一项随机对照试验的预设亚组分析
Lancet. 2009 Oct 3;374(9696):1171-8. doi: 10.1016/S0140-6736(09)61298-8. Epub 2009 Aug 27.
9
Inhaled corticosteroids for stable chronic obstructive pulmonary disease.吸入性糖皮质激素用于稳定期慢性阻塞性肺疾病
Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD002991. doi: 10.1002/14651858.CD002991.pub3.
10
Variations in FEV₁ decline over time in chronic obstructive pulmonary disease and its implications.慢性阻塞性肺疾病中时间依赖性的 FEV₁ 下降变化及其意义。
Curr Opin Pulm Med. 2013 Mar;19(2):116-24. doi: 10.1097/MCP.0b013e32835d8ea4.

引用本文的文献

1
Molecular Determinants of Lung Function Decline: A Multi- Level Analysis of Gene Expression.肺功能下降的分子决定因素:基因表达的多层次分析
Res Sq. 2025 Aug 19:rs.3.rs-7292685. doi: 10.21203/rs.3.rs-7292685/v1.
2
Respiratory Rehabilitation Index (R2I): Unsupervised Clustering Approach to Identify COPD Subgroups Associated with Rehabilitation Outcomes.呼吸康复指数(R2I):用于识别与康复结果相关的慢性阻塞性肺疾病亚组的无监督聚类方法。
Diagnostics (Basel). 2025 Aug 16;15(16):2053. doi: 10.3390/diagnostics15162053.
3
Real-World Experience of Dupilumab Treatment for Patients with COPD - A Single Center Prospective Study.
度普利尤单抗治疗慢性阻塞性肺疾病患者的真实世界经验——一项单中心前瞻性研究
Int J Chron Obstruct Pulmon Dis. 2025 Aug 6;20:2753-2760. doi: 10.2147/COPD.S525781. eCollection 2025.
4
A protocol for a pilot randomised controlled trial of a Tailored Intervention for people with moderate-to-severe Chronic Obstructive Pulmonary Disease and Co-morbidities delivered by Pharmacists and Consultant respiratory Physicians (TICC-PCP) in Scotland.苏格兰药师和呼吸科顾问医师针对中重度慢性阻塞性肺疾病及合并症患者实施的量身定制干预措施(TICC-PCP)的一项试点随机对照试验方案。
Pilot Feasibility Stud. 2025 Jul 30;11(1):105. doi: 10.1186/s40814-025-01681-x.
5
Health status, respiratory symptom and dyspnea trajectories in subjects with chronic obstructive pulmonary disease: a seven-year observation in clinical practice.慢性阻塞性肺疾病患者的健康状况、呼吸道症状及呼吸困难轨迹:临床实践中的七年观察
J Patient Rep Outcomes. 2025 Jul 11;9(1):88. doi: 10.1186/s41687-025-00923-z.
6
Relationship Between COPD Progression and Frailty Progression: A Five-year Observation in Real Clinical Practice.慢性阻塞性肺疾病进展与衰弱进展之间的关系:真实临床实践中的五年观察
Int J Chron Obstruct Pulmon Dis. 2025 Jun 14;20:1955-1964. doi: 10.2147/COPD.S512326. eCollection 2025.
7
Comparative analysis of pulmonary function decline in patients undergoing bronchoscopic lung volume reduction with endobronchial valves versus conservative treatment in emphysema management: A longitudinal coarsened exact matched analysis.支气管镜下肺减容术使用支气管内瓣膜与保守治疗在肺气肿管理中患者肺功能下降的比较分析:一项纵向粗化精确匹配分析
Chron Respir Dis. 2025 Jan-Dec;22:14799731251350709. doi: 10.1177/14799731251350709. Epub 2025 Jun 11.
8
Lung function decline and incidence of chronic obstructive pulmonary disease in participants with spirometry-defined small airway dysfunction: a 15-year prospective cohort study in China.肺活量测定定义的小气道功能障碍参与者的肺功能下降及慢性阻塞性肺疾病发病率:一项在中国进行的15年前瞻性队列研究
Respir Res. 2025 Apr 28;26(1):169. doi: 10.1186/s12931-025-03244-3.
9
Lung Function Trajectory Using Race-Specific vs Race-Neutral Global Lung Function Initiative Coefficients.使用特定种族与种族中性的全球肺功能倡议系数的肺功能轨迹
JAMA Netw Open. 2025 Apr 1;8(4):e257304. doi: 10.1001/jamanetworkopen.2025.7304.
10
Plasma club cell secretory protein reflects early lung injury: comprehensive epidemiological evidence.血浆克拉拉细胞分泌蛋白反映早期肺损伤:综合流行病学证据。
Environ Health Prev Med. 2025;30:26. doi: 10.1265/ehpm.24-00335.